Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.
Bruce Babbitt
Advertisement
Bruce Babbitt is a Principal Consultant, PAREXEL Consulting
Articles by Bruce Babbitt
Advertisement
Latest Updated Articles
- Clinical And Cost Considerations Of Developing A Biosimilar
Published: September 1st 2010 | Updated:
Advertisement
Advertisement
